@inproceedings{inproceedings, title  = {{3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2015}},

 month = {{3}},

 author = {{Parker C and Vogelzang NJ and Sartor AO and Coleman RE and Fang F and Skjorestad I and Nilsson S}},

 doi = {{10.1200/jco.2015.33.7_suppl.195}},

 volume = {{33}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{7_suppl}},

 pages = {{195-195}},

 note = {{Accessed on 2025/10/10}}}